Sutro Biopharma Cuts 33% of Workforce to Extend Cash Runway Through ADC Development Milestones
Key Insights
Sutro Biopharma announced a major organizational restructuring that will reduce its workforce by approximately one-third to focus resources on advancing its three antibody-drug conjugate programs.
The restructuring, combined with expected milestone payments, extends the company's cash runway into at least mid-2027, providing funding through key clinical milestones for its ADC portfolio.
The company remains on track to advance STRO-004, its next-generation Tissue Factor (search)-targeting exatecan ADC, into clinical trials this year with initial data expected in 2026.
Sutro Biopharma announced on September 29, 2025, a significant organizational restructuring that will reduce its workforce by approximately one-third as the oncology company focuses resources on advancing its three antibody-drug conjugate (ADC) programs. The restructuring, combined with expected near-term milestone payments, extends the company's cash runway into at least mid-2027, providing funding through critical clinical development milestones.
The South San Francisco-based company, which specializes in site-specific and novel-format ADCs, plans to prioritize the advancement of its ADC portfolio and research and development collaborations. The extended runway will support operations through the planned announcement of initial clinical data from STRO-004, its next-generation Tissue Factor (search)-targeting exatecan ADC, and the initiation of clinical studies for at least one additional ADC program.
Strategic Focus on ADC Development
"After continued review of our business and pipeline priorities, we have identified and are implementing further operational efficiencies to focus our resources where they will have the greatest impact—advancing Sutro's ADC portfolio to deliver transformative therapies for patients with cancer," said Jane Chung, Sutro's Chief Executive Officer.
The company remains on track to advance STRO-004 into clinical trials this year, with initial data expected in 2026. Chung emphasized that the restructuring extends the company's expected financial runway through critical milestones and strengthens its ability to create value for both patients and shareholders.
Next-Generation ADC Platform
Sutro's proprietary cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types. The platform fully optimizes the antibody, linker, and payload components to deliver single- and dual-payload ADCs designed for meaningful breakthroughs in cancer treatment.
The company's unique capabilities in dual-payload ADCs aim to overcome treatment resistance and redefine possibilities in cancer therapy. Sutro's pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies.
Financial Runway Extension
The operational restructuring, combined with anticipated milestone payments, provides Sutro with financial stability through key development phases. The extended cash runway into at least mid-2027 ensures the company can advance its lead programs through critical clinical milestones while maintaining focus on its core ADC platform technology.
Chung expressed gratitude to the employees affected by the restructuring, noting that "their work will remain foundational to our mission moving forward" as the company continues its focus on delivering transformative cancer therapies.